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Summary A series of monoclonal antibodies was produced by immunizing mice with fresh carcinoma of the
colon and with the cell line HT-29. These antibodies could be classified into 3 different groups: (a) those
which were HT-29 specific and reacted with no other cell line or fresh colon carcinoma samples; (b)
antibodies which reacted with HT-29 and were also reactive with a number of other in vitro cell lines; and (c)
antibodies which appeared to be specific for carcinoma of the colon cell lines in that they reacted selectively
with colon carcinoma cell lines and not with carcinoma lines derived from other tissues. It was clearly shown
by immunoperoxidase staining of both normal and neoplastic cells of the gastrointestinal mucosa, from
stomach to colon, that these antibodies were not tumour-specific. Indeed, one antibody (250-30.6) has a
remarkable specificity for secretory epithelium of any tissue whether it be found in the gastrointestinal tract,
respiratory system or urinary system. We question the existence of tumour-specific antigens detected by
monoclonal antisera described thus far, and comment on the remarkable specificity of some of the sera
produced, emphasized by the secretory cell-specific antibody described herein.
Since the introduction of somatic cell hybridization
(Kohler & Milstein, 1975) large scale efforts have
been directed towards the production of
monoclonal antibodies for the diagnosis and
therapy of cancer in man. Monoclonal antibodies
have been produced against a number of human
tumours, including melanoma (Dippold et al., 1980;
Koprowski et al., 1978; Yeh et al., 1979), lung
carcinoma (Kasai et al., 1981; Sikora & Wright,
1981), mammary carcinoma (Colcher et al., 1981;
Schlom et al., 1980, Thompson et al., 1983),
colorectal carcinoma (Herlyn et al., 1979;
Koprowski et al., 1979) as well as other tumours
(Deng et al., 1981; Kennett & Gilbert, 1979; Nadler
ct al., 1980; Ritz et al., 1980; Sikora & Phillips,
1981; Ueda et al., 1981). The majority of these
antibodies recognise either polymorphic,
monomorphic or tissue-specific determinants, whilst
others may recognise tumour-specific antigens,
although this is questionable. We now describe
three different monoclonal antibodies produced to
human colon carcinoma which define three
subgroups all apparently tumour-specific. One
group reacted only with the cell line HT-29, a
second with HT-29 and several in vitro lines of
neoplastic origin and a third, reactive with colon
carcinoma cell lines and fresh tumours obtained
from the colon. However, when a range of normal
tissues was tested with this latter antibody, it was
shown not to be tumour-specific.
Materials and methods
Cell fusion
BALB/c mice were immunized with fresh colon
carcinoma (2 x 106 cells by the i.p. route) and
boosted twice with 107 HT-29 cells (colon
carcinoma cell line Fogh & Trempe, 1975). Fresh
tumour cell lines were isolated by teasing and
filtering through a sieve, centrifuging and collecting
the pellet. The pellet was run on an Isopaque-Ficoll
density gradient, viable cells were recovered,
washed and the lymphocytes were removed by
formation of T cell rosettes (E-RFC) and then
centrifuging in another Isopaque-Ficoll gradient.
The interface was collected (>95% tumour cells),
washed in PBS and the viable tumour cells injected
into the mice. Three days later the spleens were
removed, fused with the P3-NS-1-Ag4-1 (NS-1)
mouse myeloma (1.6 x 108 spleen cells: 3 x 107 NS-l
cells) and distributed into 5 microtitre plates
(Costar, Cambridge, Mass., U.S.A.) containing
BALB/c thymus cells (7 x 105 cells per well). After
several changes of Dulbecco's Modified Eagles
Medium (Flow Laboratories, Stanmore, New South
Wales, Australia) supplemented with
Hypoxanthine-Aminopterin-Thymidine, the tissue
culture supernatants were tested for antibody
secretion using a rosetting assay (see below). Upon
screening, several antibody-producing hybridomas
were selected on the basis of their differential
reactivity with cell lines (see below). These were
cloned by limiting dilution, frozen and stored in
liquid nitrogen.
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Cell lines
All human cell lines were maintained in RPMI 1640
containing 10% heat inactivated newborn calf
serum, 4mM glutamine, penicillin (50 IUml-') and
streptomycin (50IUml- 1) (Glaxo Australia,
Boronia, Victoria) as described (Thompson et al.,
1983; Jones et al., 1982a). Adherent cells were
grown in large plastic flasks (Costar, Cambridge,
MA). and passaged by decanting the supernatant,
adding 0.125% trypsin (Commonwealth Serum
Laboratories, Parkville, Victoria) in 10% versene
for 3 min at 37°C and then stopping the reaction
with newborn calf serum (NCS). The NS-1 mouse
myeloma was grown in Dulbecco's Modified Eagles
Medium containing the same additives and used
for fusion whilst in the log-phase of growth.
Immunoglobulin class
The Ig class of the monoclonal antibodies
(concentrated 10-fold by ultrafiltration) were
determined by double gel diffusion using
monospecific rabbit antisera to the IgM, IgA, IgGl,
IgG2a and IgG2b heavy chains (Nordic
Immunological Laboratories, Tilburg, The
Netherlands).
Rosetting assay
Antibody secreted into tissue culture supernatant by
hybridomas was detected by a sensitive sheep anti-
mouse Ig rosetting assay (Parish & *McKenzie,
1978-this assay is more sensitive than either radio-
immunoassay or cytotoxicity). Briefly, 25,pl of
target cells (3 x 106mI-1) were incubated with 25pl
of antibody for 30 min at 4°C, washed 3 x in
Leibovitz-medium (L15) containing 1% bovine
serum albumin and resuspended in 25p1i of sheep
red cells (SRBC) coated with sheep anti-mouse Ig
(2mgml- 1) using chromic chloride (0.01%). After a
slow centrifugation and addition of ethyl violet the
percentage of rosetted cells was determined. (A
rosetted cell can be defined as a target cell having
bound at least 6 SRBC).
Immunofluorescence and immunoperoxidase staining
Human tissue specimens were obtained from fresh,
unfixed biopsy and autopsy material. Colorectal
carcinoma differentiation was assessed by one of
the authors (E.P.) according to conventional criteria
(Pihl et al., 1980a). The fresh tissue samples were
cut into 0.5cm blocks and snap frozen in a liquid
nitrogen-isopentane slurry and stored at -70°C
(Nairn, 1976). For indirect immunofluorescence
(Thompson et al., 1983) tissue sections (6,um) were
air dried, covered with monoclonal antibody
(supernatant) and incubated for 30min at room
temperature in a humidified chamber. The sections
were washed with 0.1M PBS (pH 7.2) and stained
with a fluoresceinated rabbit anti-mouse IgG
antiserum (Miles Laboratories, Elkhart, Indiana,
U.S.A.) for 30 min at room temperature. The
conjugate had been absorbed on a Sepharose 4B
column coupled with human IgG so that by itself it
gave no staining of sections. After washing, stained
sections were examined under a Leitz Orthoplan
fluorescence microscope by transmitted darkground
illumination with narrow-band blue excitation.
Alternate sections were fixed in 10% buffered
formalin, stained with H & E and examined by
conventional light microscopy. Supernatant from a
hybridoma producing an antibody against the
murine lymphocyte marker Lyt-1.1 was used as a
negative control for immunofluorescence.
The immunoperoxidase technique was performed
as described previously (Thompson et al., 1983).
Briefly, monoclonal antibody supernatant (1/10)
was applied to air-dried, fresh-frozen tissue sections
for 20 min. The sections were then washed for 15
min in PBS and the incubation repeated. A rabbit
anti-mouse Ig (1/100) was added to the sections for
20 min, slides were washed again for 15 min and a
swine-anti-rabbit Ig serum-conjugated with horse-
radish-peroxidase (Dako, Copenhagen, Denmark)
at 1/20 was applied for 20 min. After washing
1.5mgml-1 DAB (Sigma, St. Louis, Missouri) was
added for 5 min. Slides were then washed and
mounted for study. A monoclonal antibody which
recognises breast tissue was used as a control for
tissue staining (Thompson et al., 1983).
Blocking with xenogeneic antiserum
To determine the relationship of the antigen
detected by 250-30.6 and several other antigens,
blocking tests were performed. Normal rabbit
serum (as a control) and rabbit antisera to
carcinoembryonic antigen (CEA) (Pihl et al.,
1980a), to colonic carcinoma mucin (CCM) (Ma et
al., 1980) and to a 3 M KCI extract of colonic
tumour cells (Jones et al., 1982b) were used to coat
HT-29 cells in an attempt to block the binding of
the 250-30.6 monoclonal antibody. This was
performed by mixing 106 HT-29 cells with 300,u1 of
the different rabbit antisera at 1/4 (a dilution
representing an excess of antibody) for I h at 4°C.
The cells were then washed, centrifuged and the
incubation repeated. The coated HT-29 cells were
then incubated with the 250-30.6 antibody and the
titre determined in a SAMG-RFC assay.
Serum and antigen inhibitions
To detect antigen in serum a rosette inhibition
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patients with colorectal carcinoma, purified CEA
(1mgml-1), CCM (lmgml-1) and a 3MKCl
extract of HT-29 (1mgml-1) were serially diluted
(25,l), and then mixed with 25jul of 250-30.6
(1/200: a dilution which gave 90% rosettes) at 4°C
overnight. HT-29 cells were then added and the
bound antibody assayed by a SAMG-RFC assay
for an inhibition of RFC.
Molecular weight determination
Cell surface labelling using 1251 (Phillips &
Morrison, 1971) and internal labelling using 35S-
methionine (Jones et al., 1978) was performed with
the HT-29 target cells. After labelling, the cells were
lysed in NP-40 and the lysate reacted with the
appropriate antibody. The antigen-antibody
complex was precipitated from solution using
Staphylococcus aureus Cowan I strain, and after
reduction the molecular weight of the antigen was
determined from electrophoresed acrylamide (10%)
gels (see Thompson et al., 1983 for details).
Results
Details offusion
Nine days after cell fusion 480 microtitre wells were
screened for the production of antibody by testing
the tissue culture supernatants on the HT-29 using
the SAMG-RFC assay. Hybrids actively secreting
antibody to the HT-29 cells were found in 102/480
wells. Preliminary testing indicated that the
majority of these antibodies were also reactive with
other human cells, peripheral blood lymphocytes,
carcinoma of the lung, carcinoma of the breast,
melanoma and the Raji cell line, and these were
discarded. Seven antibodies were selected for
further study on the basis of their more selective
reactivity with colonic carcinoma cell lines; these
were cloned twice by limiting dilution and stored
frozen. Three different sets of antibodies were
subsequently studied: (a) 250-30.6; (b) HT-29
specific; and (c) HT-29 specific plus several other
reactions.
The reactivity of250-30.6 with cell lines
After cloning, supernatants were tested on a panel
of in vitro produced cell lines. The monoclonal
antibody 250-30.6 (IgG2b) bound strongly to HT-29
and gave a titre of 1:400 by the SAMG-RFC assay.
When tested on 6 other colorectal cell lines (Table
I), all were reactive, but there was no reaction with
other human cell lines, including those derived from
breast carcinoma (2), melanoma (3), gall bladder
and from lymphoid cells. The results obtained by
rosetting were all confirmed by membrane
immunofluorescence. A cell line derived from
carcinoma of the larynx (HEp-2) was weakly
positive by immunofluorescence. Thus, antibody
250-30.6, tested by the sensitive rosetting method
or by immunofluorescence appeared to be specific
for carcinoma of the colon (other than for the weak
HEp-2 reaction).
The reactivity ofother monoclonal antibodies
Six antibodies (250-9, -10, -11, -15, -17) had
a low titre (1:32), whereas 250-24, was higher on
HT-29 (1:256). These antibodies appeared to be
HT-29 specific as they did not react with the other
colorectal cell lines (Table I). However, the
antibodies 250-17 and 250-24 also reacted weakly
with the breast carcinoma (T47D); and 250-17 had
an additional reaction with a kidney carcinoma
(Colo 293). Thus 2 groups of antibodies were
defined here: (i) those which were HT-29 specific
and (ii) those with additional reactivity. Due to its
more selective reactivity with colon carcinoma lines
subsequent testing was performed only with
antibody 250-30.6.
Reaction of 250-30.6 with benign and malignant
human tumours by immunofluorescence and
immunoperoxidase
Immunofluorescent staining patterns produced by
monoclonal antibody 250-30.6 on a range of fresh
human tumours of different origin were performed
(Table II), and included several metastasising
colorectal carcinomas. It was noted that the
antibody reacted only with fresh frozen sections
and not with formalin fixed paraffin-embedded
sections.
In short, the histological studies demonstrated
that benign and malignant tumours from the
colorectal region were reactive, as were metastases,
but other tumours were non-reactive (Figures 1 and
2). The antibody also reacted with normal colonic
tissue. The details are as follows: (i) In primary
colorectal carcinoma the staining was confined to
the glandular epithelial cells of the tumour (Figures
la,b and 2b) and this was found in 12/12 tumours
with varying grades of differentiation (good,
intermediate, and poor). By contrast 4 anaplastic
primary colorectal carcinomas were non-reactive,
clearly indicating that the expression of the antigen
detected by 250-30.6 is related to the stage of
differentiation; (ii) When the colorectal tumours
had metastasized to different tissues lymph node,
liver, lung, and ovary 250-30.6 was also reactive
(Figure 1c), and gave similar staining patterns to
that found with the primary tumour; (iii) A number
of benign colorectal lesions were also examined
villous adenoma, tubulo-villous adenoma and598 C.H. THOMPSON et al.
Table I Antibody reactivity with human cell lines*
IIs'h./do/)I.
25(0- 9,10
Target cell 250-30.6 250-11,15 250-17 250-24
Colorectal carcinoma
Breast carcinoma
(Carcinosarcoma
H50578T)
Melanoma
Lung carcinoma
Leukaemia/lymphoma
Kidney carcinoma
Larynx carcinomat
Bladder carcinomat
Tongue fibroblastst
Lung fibroblasts
Peripheral blood
lymphocytes
(5 individuals)
Human red blood cells
(groups Al, A2 and B)
HT-29
Colo 205
Colo 320
Colo 321
Colo 394
Colo 397
Colo 463
T47D
Colo 525
RPMI
7932
Colo 239
M14
Mon 203
Colo 338
Raji
Daudi
HMy2
H52
UW
ARH77
Molt 4
Colo 293
HEp-2
T24
HE(39)
HLF
+
+
+
+
+
+
+
+ + +
_ + +
NT
NT
+
NT
NT
+
NT NT
NT NT
NT NT
NT NT
NT
NT
NT
NT
NT
NT
NT NT NT
*Testing was performed by the RFC assay, except where indicated and graded
as: Strong (75% RFC +), Weak (10-50% +) or Negative (< 10% RFC -).
-;-Staining assessed by immunofluorescence and graded as + (strong), +
(weak), or -(negative).
NT=not tested.
hyperplastic polyps. All of these gave strongly
immunofluorescent staining ofthe epithelium, as was
found for the colorectal carcinoma; (iv) A number
of other primary tumours obtained from the breast,
lung, kidney, anus, and thymus were examined. All
were non-reactive by immunofluoresence, as shown
(Table II).
Reaction of 250-30.6 with normal tissue bv
imm7luniofluorescence andimmunoperoxidase techniques
Monoclonal antibody 250-30.6 was tested on a
large range of adult and foetal tissue, using either
the immunofluorescence or immunoperoxidase
techniques. As similar results were obtained withMONOCLONAL ANTIBODIES TO COLORECTAL CANCER 599
Table II Reaction of 250-30.6 with benign and malignant human tumours by
immunofluorescence
Tumour Tissue
Staining of Antibody
No. staining* Description
Primary Colorectal Carcinoma:
Good and intermediate
differentiation
Poor differentiation
Anaplastic
Colorectal Carcinoma Metastases.
Lymph node
Liver
Lung
Ovary
Benign Colorectal Lesions:
Villous adenoma
Tubulo-villous adenoma
Hyperplastic polyp
Other Primary Tumours:
Breast (ductal) carcinoma
Lung (squamous) carcinoma
Kidney (renal cell) carcinoma
Squamous carcinoma of anus
Thymoma
12/12 Tumour glandular epithelial
cells strongly positive
3/3 Tumour epithelium, weaker
than above
0/4
3/3
2/2
1/1
1/1
2/2
1/1
2/2
0/2
0/2
0/2
0/1
0/1
No staining
Staining of tumour cells
Staining of tumour cells
Staining of tumour cells
Staining of tumour cells
Strong staining of
adenomatous epithelium
Strong staining of
adenomatous epithelium
Glandular epithelial cells
strongly positive
No staining
No staining
No staining
No staining
No staining
*Positive no of specimens tested.
both techniques, the results are pooled and shown
in Table III. The studies clearly demonstrate that in
addition to benign and malignant tumours of the
gastrointestinal tract and their metastases, normal
tissues are also reactive (Figures Id and 2a; Table
III). Thus in Table III it can be shown that
glandular epithelial cells obtained from the
stomach, pancreas, gall bladder, ileum and colon
and rectum were all reactive. Moreover the staining
was also found on normal tissue obtained from
other organs. Thus larynx, trachea, bronchus,
prostate and uterus, all showed staining of the
mucous secreting glandular cells within these tissues
(Figure ld). However, not all tissues were reactive
and a large number of other tissues were non-
reactive as shown (Table III). The
immunofluorescent and immunoperoxidase
techniques gave very similar but not identical
results. The discrepancy was attributed to the
increased sensitivity of the 3-layer
immunoperoxidase technique, as opposed to the 2-
layer sandwich used in immunofluorescence.
Thus antibody 250-30.6 is clearly not tumour-
specific, even though our first results indicated this
A*
to be so (Tables I and II). Clearly, as more tissues
were examined the antibody appeared to be colon-
specific, but later this was amended to specific for
the secretory epithelium of certain tissues.
Inhibition with sera from patients with colon
carcinoma
To determine whether the antibody 250-30.6 could be
of value as a diagnostic or monitoring reagent, the
serum of ten patients with colorectal carcinoma
taken pre- and post-operatively and 10 normal
individuals (age- and sex-matched) were tested for
their ability to bind to the monoclonal 250-30.6
antibody (Table IV). The sera of normal individuals
had no inhibitory effect on 250-30.6, but 7/10 post-
operative sera inhibited the binding of 250-30.6 to
HT-29, indicating that the antigen recognized by
250-30.6 is shed into patients' serum. By contrast
only 3/10 pre-operative sera were inhibitory.
Typical inhibition data for 3 normal and 2 cancer
patients are shown diagrammatically in Figure 3. An
effort to quantitative these serum inhibition results
is shown in Table IV. For each patient the600 C.H. THOMPSON et al.
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Figure 1 Immunofluorescent staining of frozen tissue sections by monoclonal antibody 250-30.6 ( x 100). (a)
Glandular cell staining of colorectal adenocarcinoma of intermediate differentiation. (b) Deposit of poorly
differentiated, weakly stained colorectal carcinoma cells (arrows), in comparison with the more strongly
stained normal colonic mucosal glands (lower left). (c) Staining of metastatic colorectal cancer cells in the
stroma of liver. (d) Glandular staining of mucous acini of normal human bronchus.
"inhibitory units" (I.U.) perml of serum were
calculated on the basis of the antibody dilution
which gave a 25% inhibition of the maximum
number of rosettes formed, using 25,ul of patients'
serum. The inhibition appeared to be unrelated to
tumour stage or differentiation, but it was
interesting to see that inhibition was absent from
the two "A" stage patients, and the majority of
inhibition occurred in sera taken post-operatively.
Demonstration that antigen detected by 250-30.6 is
distinctfrom CEA and colon carcinoma mucin
To determine if the monoclonal antibody 250-30.6
was recognizing CEA or CCM, blocking
experiments with xenogeneic antibodies to these
antigens were performed. As shown in Figure 4a
the reaction of 250-30.6 was the same whether HT-
29 was treated with normal rabbit serum, rabbit
anti-CEA or rabbit anti-CCM, indicating that the
antigenic determinant recognized by 250-30.6 is
distinct from CEA or CCM. Rabbit antiserum to a
3 M KCI extract of HT-29 partially inhibited the
binding of 250-30.6.
These studies were pursued further by attempting
to inhibit the reaction of the 250-30.6 antibody
using purified CEA, CCM or crude HT-29
preparations (Figure 4b). These components were
incubated with 250-30.6 which was then tested on
HT-29. It is clear that purified CCM had no
inhibitory effect. A partial inhibition occurred with
purified CEA, but this was very much less than the
inhibition obtained with the HT-29 cell lysate, and
is likely to be non-specific. Both an NP-40 cellMONOCLONAL ANTIBODIES TO COLORECTAL CANCER 601
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Figure 2 Immunoperoxidase staining of tissue sections (x 250). The staining of normal colon (a) and
carcinoma of the colon (b), by the 250-30.6 antibody using the immunoperoxidase technique.
100 ~~~~~~~~~~lysate and a 3 M KCl extract derived from HT-29
_______ _______________ substantially inhibited the binding of 250-30.6 to
...-MEHT-29.
80 ,!". Mokeular weight estimation
After internal labelling, two heavily-labelled bands
60 (25 Kd and 27Kd) were detected and a lighter band
(22Kd). was also detected (Figure 5, Lane B). A
-. ~~~~~~number of other bands, also present, were artefacts
40 (as shown by comparison with normal mouse
* ~~~~~~serum, Lane A; or another monoclonal antibody,
20 Lane C). Surface labelling with 121 revealed several
bands of 22, 27, 31 and 42 Kd (Figure 5, Lane E).
The reasons for the additional bands are not clear, - p_. I but investigations are in progress to clarify this.
0 2 4 8 16
Serum, dttm;
Discussion
Figure 3 Typical serum inhibition results. The
binding of 250-30.6 to HT-29 was inhibited by serum
from two patients with colorectal carcinoma (O----O)
and X-X), but not by serum from normal individuals
(O 0,**-, 0-0).
In this report we describe a series of monoclonal
antibodies produced by immunizing BALB/c mice
with colorectal carcinoma, and fusing their spleen
cells with the NS-1 mouse myeloma. The majority
C.) IL.
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Table III Reaction of 250-30.6 with normal human tissues by immunofluorescence
and immunoperoxidase
Staining ofAntibody
No.
Tissue Staining* Description
Adidzt Tis.sue (Positive)
Colon/Rectum
Ileum
Stomach
Pancreas
Gall Bladder
Larynx
Trachea
Bronchus
Prostate
Uterus
Skin
Salivary gland
Kidney
Liver
5/5
2/2
2/2
1/1
2/2
2/2
3/3
2/2
2/2
2/2
2/2
2/2
2/2
2/2
Glandular and epithelial cells
strongly positive
Glandular and epithelial cells
strongly positive
Glandular and epithelial cells
strongly positive
Ductal epithelial cells positive
Epithelial cells positive
Mucous acinar cells positive
Mucous acinar cells positive
Mucous acinar cells positive
Glandular epithelial cells positive
Glandular epithelial cells positive
Negative by immunofluorescence
but positive by immunoperoxidase
Negative by immunofluorescence
but positive by immunoperoxidase
Negative by immunofluorescence
but positive by immunoperoxidase
Negative by immunofluorescence
but positive by immunoperoxidase
Adutilt Tissue (Negative)
adrenal gland, bladder, breast, epididymis, fallopian tube, lung, lymph node, ovary,
parathyroid gland, parotid gland, testis, thyroid, ureter, thymus, tonsil, spleen.
Foetal Tissues (Positive)
Colon 3/3 Glandular and epithelial
Small Intestine 2/2
cells positive
Glandular and epithelial
cells positive
Foctal Tissues (Negative)
Salivary gland, thymus, trachea
Adult Animlal Tissues (Negative)
Dog stomach, guinea-pig colon, mouse stomach, rabbit colon and liver, rat colon and
kidney.
*Number of specimens tested by immunofluorescence or immunoperoxidase.
of antibodies (250-9, 250-10, 250-11, 250-15 and
250-24) appear to recognize antigens restricted to
HT-29 as the other colorectal carcinomas (Colo
205, Colo 320, Colo 397) were non-reactive. On
further testing the monoclonal antibodies 250-17
and 250-24 were found to be also reactive with
malignant breast epithelium, and 250-17 also
appears to recognize an epithelial antigen present in
carcinoma of the kidney but not in other tissues
(Table I). The findings raise the possibility that
epithelial "subsets" may exist, similar to the
lymphocyte subsets defined by the OKT (human)
and Ly (mouse) series of monoclonal antibodies.
One monoclonal antibody, 250-30.6, reacted
strongly with all 7 colorectal carcinoma cell lines
but very weakly with a laryngeal carcinoma (Table
I). Other human cells were also tested with this
antibody and these were found to be non-reactive,
including 19/20 cells lines, erythrocytes, peripheral
blood lymphocytes. Thus on limited testing of cell
lines this antibody appears to be colon carcinoma-
specific. However, we felt that examination of many
tissues, both normal and malignant, was necessary
for the definition of antigens identified by
monoclonal antibodies. Therefore the 250-30.6
monoclonal antibody was tested byMONOCLONAL ANTIBODIES TO COLORECTAL CANCER
Table IV Inhibition of binding of 250-30.6 to HT-29
colorectal cancer
by sera* from patients with
Inhibition unitst
Patlienlt Duke'S Pre- Post-
.%(eruI//t1 staging Diagnosis operatively operativel/
Shu D Tumour metastases 0 100
Del B Tumour growth in tissues 0 200
adjoining colon and rectum
Mar C Infiltrating tumour with 266 170
lymph node involvement
Tot B Tumour growth in tissues 132 176
adjoining colon and rectum
DalI B Tumour growth in tissues 0 0
adjoining colon and rectum
Pow A Tumour confined to intestinal wall 0 106
Cle A Tumour confined to intestinal wall 0 0
Day B Tumour growth in tissue 0 0
adjoing colon and rectum
Phi B Tumour growth in tissue 0 168
adjoining colon and rectum
Mul B Tumour growth in tissue 160 200
adjoining colon and rectum
*Sera from normal volunteers were all non-
tlnhibition Units (1.U.) are calculated
(multiplication factor needed to yield I ml).
immunofluorescence and immunoperoxidase and
was found to detect an antigen on both malignant
and normal tissue. The cell membrane and
cytoplasm of normal human glandular epithelium
and surface epithelial cells of the gastrointestinal
tract, and the submucosal mucous acinar cells, but
not the surface epithelial cells of the respiratory
tract were also reactive. In addition, the staining
pattern of these cells was clearly cellular and no
luminal products stained, i.e. mucin. This would
indicate that the antigen involved is not a secretory
product per se and that the cells lining the
gastrointestinal and respiratory tracts differ with
respect to the presence of this antigen. The
antibody also reacted with cells lining the glands of
the prostate and uterus. These organs have cyclical
growth phases (Wheater et al., 1979) and it would
be of interest to determine whether the presence of
the antigen is indicative of any specific part of their
secretory cycle.
It was interesting to discover that the monoclonal
antibody 250-30.6 will also bind directly to fresh
operative colonic tumour cells (data not shown),
and the immunofluorescent staining of colorectal
carcinoma showed that the fluorescence intensity of
the reaction decreased progressively with tumour
dedifferentiation. This apparent inverse relationship
between antigen density and increasing malignant
potential (as expressed by glandular
as follows: LU. = 1/antibody dilution x 40/1
dedifferentiation) is similar to that of CEA which
has been shown to be produced in largest quantities
by colonic carcinoma cultures (Zamcheck, 1981)
obtained from well differentiated tumours, although
the serum levels are higher in poorly differentiated
tumours (Pihl et al., 1980b) probably reflecting
sequestration in the former and extensive spread of
the latter. The antigen detected by 250-30.6 did not
appear to be CEA or CCM as: (i) purified CEA,
and CCM when incubated with the 250-30.6
antibody did not alter antibody binding to HT-29
(ii) HT-29 coated with rabbit antisera to CEA and
CCM did not block the binding of 250-30.6, and
(iii) the molecular weights of these antigens are
significantly different from the antigen defined by
250-30.6.
It is of interest to note that the sera of 30% of
pre-operative colorectal carcinoma patients inhibit
the binding of 250-30.6 to HT-29, indicating that
the antigen (although not tumour-specific)
recognised by 250-30.6 or the monoclonal antibody
could be useful for therapy. Studies examining these
possibilities are currently in progress.
In summary it is therefore clear that limited
examinations confined to tumour cells lines are not
adequate and that extensive studies on a wide
variety of normal tissues including those of foetal
origin should be performed using primarily
histological techniques such as immunofluorescence
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Figure 4a Reaction of monoclonal antibody 250-30.6
with HT-29 in the presence of antisera. HT-29 coated
with (i) rabbit anti-3M KCI extract of HT-29 (0-0);
(ii) rabbit anti-CEA (0----@); (iii) rabbit anti-CCM
(O O); (iv) normal rabbit serum (X----X), or
untreated (0 0).
~40
o: 2 8 16 32 64
* ~~~An_l dMon-
Figure 4b Inhibition of 250-30.6 binding to HT-29
after incubation with purified CEA (0----@), purified
CCM (El El), a 3M KCl extract of HT-29 (O----O),
an NP-40 lysate of HT-29 (0-0), or PBS (X-X).
Figure 5 Autoradiographs of SDS-PAGE of HT-29 after being internally labelled with [35S]-Methionine
(Lanle A, B, C) and after being surface labelled with 1251 (Lane D, E, F). In the [35S]-Methionine labelling,
Lane A corresponds to the bands reactive with the normal mouse serum control, Lane B corresponds to the
molecules precipitated by the monoclonal antibody 250-30.6, and Lane C is a monoclonal antibody control.
For 125 labelling, Lane D represents the normal mouse serum control, Lane E corresponds to 250-30.6 and
Lane F another monoclonal antibody control.
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or the more sensitive immunoperoxidase method. In
this context the tumour specificity of 250-30.6
disappeared, i.e. the antibody defines an interesting
differentiation antigen of epithelial cells, selectively
reacting with those of the secretory type.
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